Amelioration of the disease phenotype in TregPMA cell treated mice. Mice that were injected with CD45RBhigh cells only developed colitis (positive control group, n = 9) while the mice that were injected with CD45RBhigh and CD45RBlow cells together remained healthy (negative control group, n = 10). The experimental group was injected with CD45RBhigh and TregPMA cells (n = 10). Disease progression was assessed by changes in weekly body weight (A) as well as macroscopic and microscopic scores at day of sacrifice which comprises of Disease Activity Index (C) and Histological Score (D). TregPMA cell treated mice showed to have reduced weight loss over time (A) and at the time of sacrifice (B) when compared to positive control. The change of weight is expressed as the mean percentage of initial weight per group ± SD. Disease Activity Index (DAI), calculated from combining scores applied to weight loss, stool consistency at sacrifice and rectal bleeding divided by three, shows a significant difference between groups (C) as well as Histological Score of the H&E stained colon tissue sections (D). The data were analyzed using one-way ANOVA, followed by Bonferroni’s Multiple Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Majowicz et al. BMC Gastroenterology 2012 12:172 doi:10.1186/1471-230X-12-172